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ABSTRACT 
 
Tumor necrosis factor (TNF) receptor-associated factor 3 (TRAF3) functions 
downstream of multiple TNF receptors and other receptors which induce interferon-α 
(IFN-α), IFN−β and IFN-λ production, including TLR3 which is deficient in some 
patients with herpes simplex virus-1 (HSV-1) encephalitis (HSE). Mice lacking TRAF3 
die in the neonatal period, preventing direct investigation of the role of TRAF3 in 
immune responses and host defenses in vivo. Here we report autosomal dominant, 
human TRAF3 deficiency in a young adult with a history of HSE in childhood. The 
TRAF3 mutant allele is loss-of-expression, loss-of-function, dominant-negative, and 
associated with impaired, but not abolished TRAF3-dependent responses upon 
stimulation of both TNF receptors and receptors which induce IFN production. 
Nevertheless, TRAF3 deficiency is associated with a clinical phenotype limited to HSE 
and resulting from the impairment of TLR3-dependent induction of IFN-α/β and –λ. 
Thus, TLR3-mediated immunity against primary infection by HSV-1 in the central 
nervous system is critically dependent on TRAF3. 
 
Highlight sentence: Autosomal dominant TRAF3 deficiency is a genetic etiology of 
herpes simplex encephalitis. 
Highlight sentence: The R118W TRAF3 allele is loss-of-function, loss-of-expression, 
and dominant-negative. 
Highlight sentence: Human TRAF3 deficiency impairs the TLR3-dependent induction 
of anti-viral interferons. 
 
 
 
 3 
INTRODUCTION  
Herpes simplex virus (HSV-1) encephalitis (HSE) is a devastating infection of 
the central nervous system (CNS) (Whitley, 2006). HSE is the most common form of 
sporadic viral encephalitis in Western countries, in which its incidence has been 
estimated at approximately 1 in 250,000 individuals per year. The disease peaks in 
childhood, between the ages of three months and six years. During primary infection 
with HSV-1, the virus reaches the CNS via a neurotropic route involving the trigeminal 
and olfactory nerves (Abel et al.; De Tiege et al., 2008). Acyclovir treatment decreases 
the mortality rate in affected children, but substantial neurological impairment is 
nevertheless observed in most survivors, and in particular, in young children. However, 
HSV-1 is widespread and typically innocuous in human populations. 
Childhood HSE was not associated with known immunodeficiencies and the 
mechanism of its pathogenesis remained elusive until we identified the first two genetic 
etiologies of this condition: autosomal recessive UNC-93B deficiency, which abolishes 
Toll-like receptor 3 (TLR3), TLR7, TLR8, and TLR9 signaling (Casrouge et al., 2006), 
and autosomal dominant TLR3 deficiency, which specifically affects TLR3 signaling 
(Zhang et al., 2007). These findings are consistent with the lack of HSE in patients with 
IRAK-4 and MyD88 deficiencies, as these patients have a functional TLR3, but non 
functional TLR7, TLR8, and TLR9 (Picard et al., 2003; von Bernuth et al., 2008; Yang 
et al., 2005) 
Our previous demonstration that STAT1 deficiency, unlike IFN-γR1 or IFN-γR2 
deficiency, confers predisposition to multiple viral diseases, including HSE, suggested 
that impairment of the TLR3-dependent production of IFN-α and IFN-β (type I IFN) 
and IFN-λ (type III IFN) might account for HSE in patients with TLR3 and UNC-93B 
deficiencies (Chapgier et al., 2009; Dupuis et al., 2003). Collectively, these studies 
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suggest that childhood HSE may result from impaired type I and/or type III IFN 
production in response to the stimulation of TLR3 by dsRNA intermediates of HSV-1 in 
the CNS, in at least some children. As only a small fraction of children with HSE carry 
mutations in the TLR3 and UNC-93B genes, we searched for mutations in other genes 
controlling the TLR3 pathway. Here, we report on an autosomal dominant deficiency of 
the TRAF3 adaptor protein in a patient with HSE. This experiment of Nature indicates 
that TLR3-mediated immunity against primary infection by HSV-1 in the central 
nervous system is critically dependent on TRAF3. 
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RESULTS 
Heterozygous TRAF3 mutation in a patient with HSE 
We investigated an 18-year-old French girl (P1) who had suffered from HSE at 
the age of four years (Supplemental data text, note 1) and carried no mutation in the 
coding region of UNC93B1 or TLR3, the mRNAs of which were normally spliced and 
generated in normal amounts. No mutations were found in the coding regions of seven 
other genes known to control the TLR3 – type I IFN pathway, encoding Toll-IL-1 
receptor domain-containing adaptor protein-inducing IFN-β (TRIF), TRAF-interacting 
protein I-TRAF (TANK), the adaptor protein SINTBAD, NAK-associated protein-1 
(NAP1), TANK-binding kinase 1 (TBK1), Iκ-B kinase-ε (IKK-ε), and the transcription 
factor IRF-3. A heterozygous substitution (CT) was found at nucleotide position 352 
(c.352C>T) in exon 4 of the gene encoding TNF receptor-associated factor 3 (TRAF3) 
(Bishop and Xie, 2007; Hacker et al., 2006; He et al., 2007; Oganesyan et al., 2006) in 
genomic DNA (gDNA) from the granulocytes, EBV-transformed B cells (EBV-B cells), 
and SV40-transformed fibroblasts (SV40-fibroblasts) of P1 (Fig. 1A and B). No other 
mutations were found in the coding region of TRAF3. The TRAF3 mutation is missense 
and non conservative, as it replaces an Arg residue at position 118 in the first of the five 
zinc-finger domains with a Trp residue (R118W) (Fig. 1C). R118W was not found in 
the NCBI and Ensembl databases or in up to 1,209 unrelated healthy individuals (2,418 
chromosomes) from the CEPH-Human Genome Diversity panel examined, including 
289 Europeans, ruling out an irrelevant polymorphism. The father, mother and brothers 
of P1 do not carry the R118W mutation. Alignment of the human TRAF3 sequence with 
sequences from the 13 animal species in which TRAF3 has been sequenced showed 
R118 to be strictly conserved throughout evolution (Fig. S1). These data suggest that 
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the de novo R118W germline mutation in TRAF3 may be responsible for the autosomal 
dominant predisposition to HSE in P1. 
 
Impaired TRAF3 production in cells from the patient  
We then assessed the expression of TRAF3 mRNA and protein in cells from P1. 
Quantitative PCR showed baseline TRAF3 mRNA expression in SV40-fibroblasts 
(human fibroblasts immortalized with SV40) (Fig. 2A) and EBV-B cells (human B cells 
immortalized with EBV) (Fig. S2A) from P1 to be normal. The wild-type (WT) and 
mutant TRAF3 alleles were expressed to similar extents, as shown by direct sequencing 
of the RT-PCR product (data not shown). In contrast, TRAF3 protein in SV40-
fibroblasts (Fig. 2A) and EBV-B cells (Fig. S2B) from P1 were only about 17.5% those 
in five unrelated healthy controls (data not shown), as shown by immunoblot analysis. 
Similar results were obtained with two additional antibodies recognizing different 
TRAF3 epitopes at some distance from residue 118 (Fig. S2C). The R118W mutation 
therefore seems to prevent stable TRAF3 protein production. It also seems to have an 
effect on the amount of WT protein generated from the other allele. We stably 
transfected a TRAF3-knockdown RAW mouse macrophage cell line (RAW Traf3-/-) 
(Tseng et al., 2010) with vectors encoding the WT or R118W human TRAF3 allele. 
TRAF3 protein was detected after transfection with the WT construct, but not after 
transfection with the mock vector or the R118W allele, whereas mRNA was detected 
for both the WT and R118W forms (Fig. 2B).  
 
Impaired TLR3 responsiveness of the patient’s fibroblasts 
The induction of IFN-β and, subsequently, of IFN-inducible target genes in 
response to TLR3 agonists is markedly impaired in bone marrow-derived macrophages 
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(BMMs) generated from irradiated C57BL/6 mice, reconstituted with Traf3-/- fetal liver 
cells (Hacker et al., 2006; Oganesyan et al., 2006). We investigated the contribution of 
TRAF3 deficiency to the pathogenesis of HSE in P1, by evaluating the TLR3 pathway 
in SV40-transformed dermal fibroblasts, in which the response to poly(I:C) is TLR3-
dependent (Casrouge et al., 2006; Zhang et al., 2007). In control SV40-fibroblasts, IFN-
β, IFN-λ and IL-6 were secreted in a time- and dose-dependent manner, after TLR3 
stimulation with poly(I:C) (Fig. 2C). In contrast, cells from P1 and from an UNC-93B-
deficient patient did not respond. TNF-α-induced IL-6 production was normal, 
indicating that the differences in IFN-β, IFN-λ and IL-6 production upon TLR3 
stimulation were not due to a general non-responsiveness of the cells (Fig. S2D). 
Similar results were obtained for the IFN-β and IFN-λ mRNAs (Fig. S2E) and for 
analyses of primary dermal fibroblasts (data not shown).  
We dissected the cellular phenotype of P1 further, by studying two transcription 
factors controlling the TLR3-IFN pathway: NF-κB and IRF-3. Accumulation of the NF-
κB p65 subunit in the nucleus in response to poly(I:C) was impaired in P1, as shown by 
ELISA (Fig. 2D), whereas the response to both TNF-α and IL-1β was normal. In 
contrast, the dimerization of IRF-3 in response to poly(I:C) in SV40-fibroblasts from P1 
was less strongly affected, as shown by comparisons with healthy controls and with 
TLR3-deficient and UNC-93B-deficient cells (Fig. 2E) (Casrouge et al., 2006; Zhang et 
al., 2007). The TRAF3 deficiency therefore affected the TLR3 pathway, in terms of the 
activation of NF-κB and, to a lesser extent, IRF-3. This resulted in the impairment of 
cytokine production, with the abolition of IFN-β, IFN-λ and IL-6 induction by 
poly(I:C), in particular.  
 
Complementation of the patient’s cells with wild-type TRAF3 
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P1 fibroblasts were transfected with WT TRAF3 and stable transfectants were 
obtained (Fig. 3A). These cells contained no more than about 30% the amount of 
TRAF3 present in healthy controls. However, they contained more TRAF3 than non 
transfected and mock-transfected P1 cells, which contained only about 17.5% the 
amount of TRAF3 present in controls (Fig. 3A), consistent with the mutant allele being 
structurally dominant-negative. Nevertheless, stable transfection with the WT TRAF3 
allele, unlike mock transfection, complemented the defect in the TLR3-dependent 
induction of IFN-β, IL-6 (Fig. 3B) and IFN-λ (Fig. S3A), indicating that the doubling of 
TRAF3 amounts, although modest, was sufficient to overcome the functional defect. No 
complementation of the phenotype was observed after transfection with R118W TRAF3 
(Figures S3B and S3C). Thus, the WT TRAF3 allele complemented the lack of response 
to TLR3 in P1 fibroblasts, strongly suggesting that the patient’s fibroblastic phenotype 
and, by inference from TLR3 and UNC-93B deficiencies (Casrouge et al., 2006; Zhang 
et al., 2007), the patient’s clinical phenotype of HSE, resulted from TRAF3 deficiency. 
 
The TRAF3 mutant allele is dominant-negative 
The WT TRAF3 allele conferred functional complementation of cells from P1, 
but TRAF3 protein levels remained lower (~30%) than those in the cells of all healthy 
controls tested. This finding is consistent with the much lower than expected amounts of 
TRAF3 in the heterozygous cells of P1 (~ 17.5%). Thus, although the R118W allele is a 
loss-of-expression allele, it may exert a dominant-negative effect, by destabilizing 
proteins produced from the WT allele. Mouse RAW macrophages were used to test this 
hypothesis, because human and mouse TRAF3 proteins are 97% identical and the 
antibodies recognizing human TRAF3 also recognize its mouse ortholog. The amounts 
of mouse TRAF3 in RAW cells stably transfected with human R118W TRAF3 were 
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only about 50% those in non transfected RAW cells, mock-transfected cells or cells 
transfected with human WT TRAF3 (Fig. 3C). Similar results were obtained in transient 
transfection experiments (data not shown). However, this had no functional 
consequences, as IFN-β production after stimulation with poly(I:C) was normal, 
implying that the small amount of protein produced was nonetheless sufficient to 
activate the TLR3 pathway (Fig. 3D), a finding consistent with the successful 
complementation of the patient’s cells by only about 30% the amount of WT human 
TRAF3 generally found in normal cells (Fig. 3A). Similar results were obtained when 
SV40-fibroblasts were stably transfected with the same vectors (Fig. S3D and S3E). 
Moreover transient transfections of RAW Traf3-/- cells showed the R118W mutant form 
to have a dominant-negative effect. In cells co-transfected with a 1:1 ratio of WT 
TRAF3 and mock vector or R118W TRAF3, we found that TRAF3 protein expression 
was 30% lower in the presence of the mutant form (Fig. S4A). The co-transfection of 
cells with different ratios of WT:R118W TRAF3 showed that TRAF3 protein expression 
decreased as the proportion of the mutant form increased (Fig. S4A) Moreover, co-
transfection with a fixed amount of WT TRAF3 and increasing amounts of mutant 
TRAF3 confirmed the negative dominance by revealing a dose-dependent impact of the 
mutant allele, in terms of TRAF3 expression (Fig. S4A). 
We further investigated the possible effect of the mutant form on the stability of 
trimer formation, by generating TRAF3 deletion constructs without the C-terminal 
region implicated in trimer assembly. The deletion of this region from both the WT and 
R118W forms had no effect on TRAF3 expression in RAW Traf3-/- cells co-transfected 
with the wild-type and deletion constructs (Fig. S4A). Similar results were obtained 
after the co-transfection of cells with the WT construct and other shorter deletions of 
TRAF3 (data not shown). The dominant-negative effect of the R118W allele probably 
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resulted from the inhibition of TRAF3 trimer formation (Pullen et al., 1999), as the 
patient’s TRAF3 expression (17.5%) was close to the expected frequency of 
homotrimers composed of WT subunits only (12.5%) (Fig. S4B). Unstable 
heterotrimers may be more susceptible to protein degradation, resulting in the 
persistence within cells of only the remaining stable homotrimers. Thus, the R118W 
TRAF3 allele exerts a dominant-negative effect in various types of mouse and human 
cells, by decreasing production of the WT protein, thus accounting for the much lower 
total amount of TRAF3 present and the profound impairment of TLR3 responses in 
cells from this heterozygous patient.  
 
Impaired IFN-dependent control of viruses in TRAF3-deficient fibroblasts 
We studied fibroblast responses to vesicular stomatitis virus (VSV) infection, 
which have been shown to be impaired in UNC-93B-deficient and TLR3-deficient 
patients (Casrouge et al., 2006; Zhang et al., 2007). IFN-β, IFN-λ and IL-6 were 
produced in smaller amounts by P1 and UNC-93B-deficient SV40-fibroblasts than by 
control cells (Fig. 4A). The survival of the patient’s SV40-fibroblasts was found to be 
markedly lower than that of control cells, after 24 hours of VSV infection (Fig. 4B). P1 
cells behaved like the cells of patients with TLR3, UNC-93B and STAT1 deficiencies 
(Casrouge et al., 2006; Chapgier et al., 2009; Zhang et al., 2007). Treatment with 
exogenous IFN-α2b complemented the phenotype of TRAF3-deficient, TLR3-deficient 
and UNC-93B-deficient cells, but not that of STAT1-deficient cells (Fig. 4B). We also 
showed that control cells contain VSV replication, whereas cells from P1 and from 
patients with STAT1, UNC-93B and TLR3 deficiencies did not (Fig. 4C). When cells 
from P1, UNC-93B-deficient and TLR3-deficient patients were subjected to prior 
treatment with IFN-α2b, complementation was observed, as viral replication was 
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contained; no such complementation was observed for STAT1-deficient cells (Fig. 4C). 
Finally, we attempted to complement the TRAF3 deficiency in these assays of cytokine 
production, viral replication, and cell death. The production of IFN-β, IFN-λ and IL-6, 
cell survival and viral replication in response to viral infection were restored in P1 cells 
stably transfected with the WT construct, but not in cells transfected with the mutant 
human TRAF3 allele or the mock vector (Fig. 4D-F , S3A and S3C). Thus, P1 cells 
display impaired IFN-β production in response to VSV infection, resulting in higher 
viral replication and cell death, and this phenotype, which is also common to UNC-93B-
deficient and TLR3-deficient cells, results from TRAF3 deficiency. These findings 
identify TRAF3 deficiency as a genetic etiology of HSE, causing disruption of the 
TLR3-dependent induction of anti-viral type I IFN and IFN-λ. 
 
Impact of TRAF3 deficiency on other IFN-inducing pathways 
We also analyzed the impact of TRAF3 deficiency on other pathways, starting 
with the anti-viral pathways inducing type I IFN and IFN–λ (Bishop and Xie, 2007; He 
et al., 2007). Previous studies established a role for TRAF3 in the TLR4, TLR7-TLR8 
(Hacker et al., 2006; Hoebe and Beutler, 2006; Oganesyan et al., 2006) and RIG-I and 
MDA-5 pathways (Michallet et al., 2008). After the activation of TLR4 (LPS) and 
TLR7-TLR8 (R-848), monocyte-derived dendritic cells (MDDCs) from P1 produced 
smaller amounts of IFN-α, IL-12p40 (Fig. 5A), TNF-α, IL-6, and IL-10 (Fig. S5A) than 
cells from eight control subjects. Similar results were obtained after the activation of 
TLR4 and TLR7-TLR8 in monocyte-derived macrophages (MDMs), in terms of the 
production of IFN-λ, IL-12p40 (Fig. 5B), TNF-α, and IL-6 (Fig S5B). TRAF3 is also 
involved in the RIG-I and MDA-5 pathway. We therefore tested this pathway in SV40-
fibroblasts. After activation with poly(I:C) plus Lipofectamine or in vitro transcribed 
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5’PPP-ssRNA (7sk-as), the amounts of secreted IFN-β, IFN-λ and IL-6 were lower than 
those of control cells, UNC-93B-deficient cells (Fig. 5C) and P1 SV40-fibroblasts 
transfected with WT TRAF3 (Fig. S5C). Poly(I:C) plus Lipofectamine is known to 
activate both the RIG-I and MDA-5 pathways, whereas in vitro transcribed 5’PPP-
ssRNA (7sk-as) has been shown to be a RIG-I-specific agonist (Pichlmair et al., 2006). 
These pathways — the RIG-I pathway in particular — are therefore apparently TRAF3-
dependent in human dermal fibroblasts. Finally, we assessed the overall impact of 
TRAF3 deficiency on the production of type I IFN and IFN-λ, by investigating the 
response to several viruses in various cell types. After 40 hours of stimulation, 
peripheral blood mononuclear cells (PBMC) from P1 produced IFN-α (Fig. 5D) and IL-
6, IL-10 and IL-12p40 (Fig. S5D, E and F) in response to the 10 viruses tested, in 
amounts similar to or smaller than those produced by control cells. We investigated the 
production of IFN-β and IFN-λ in SV40-fibroblasts, after stimulation with HSV-1 (Fig. 
5E) and with four other viruses (VSV, para-III, Sindbis virus and EMCV) (Fig. 5F). P1 
fibroblasts had a broader phenotype than cells from healthy controls, UNC-93B-
deficient, TLR3-deficient and MyD88-deficient patients. Thus, TRAF3 deficiency in 
the patient broadly affected type I and type III IFN inducing pathways. 
 
Impact of TRAF3 deficiency on TNFR pathways 
TRAF3 was initially shown to interact with various TNFRs, such as CD40, LT-
βR, and BAFFR, in particular (Bishop and Xie, 2007; He et al., 2007). It was 
subsequently found to operate downstream from these receptors, as a negative regulator 
of the alternative NF-κB pathway (He et al., 2006; Vallabhapurapu et al., 2008; 
Zarnegar et al., 2008). We first analyzed the CD40 pathway (Cheng et al., 1995; 
Graham et al., 2009). P1 MDDC showed impaired production of IL-6 and IL-12p40 
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after CD40L activation (Fig. 6A and B). We also activated fresh B cells from P1 (who 
has normal counts of the main circulating B-cell subsets, as defined by IgM and CD27 
expression) with CD40L and IL-4 and observed an impairment of proliferation and Ig 
class switch recombination to IgE (data not shown). When EBV-B cells from P1 were 
activated with CD40L, the p52 product was generated without stimulation and was 
therefore constitutively activated, whereas p52 activation was not constitutive in healthy 
controls (Fig. S6A). CD40-deficient cells served as negative controls (Conley et al., 
2009). TRAF3 is also involved in the lymphotoxin-β receptor (LTβR) pathway in 
humans and mice, inducing caspase-3-independent cell death and IL-8 production 
(Chen et al., 2003; Kuai et al., 2003). P1 SV40-fibroblasts displayed lower amounts of 
cell death than control cells (Fig. 6C) or P1 cells transfected with WT-TRAF3 (Fig. 
S6B) after LT-α1β2 stimulation. Moreover, P1 cells produced smaller amounts of IL-8 
than control cells and P1 SV40-fibroblasts transfected with WT-TRAF3 (P1-WT) (Fig. 
6D).  
TRAF3 also controls IL-10 production in response to B cell-activating factor 
receptor (BAFF-R) activation in human and mouse cell lines (Gardam et al., 2008; 
Sasaki et al., 2008; Xu and Shu, 2002). After the activation of BAFF in EBV-B cells, 
the p52 product was generated without stimulation (i.e. it was constitutively activated) 
in cells from P1, but not in cells from healthy controls (Fig. 6E). Similarly, ELISA after 
BAFF activation in EBV-B cells showed that P1 cells produced more IL-10 than control 
cells and that this IL-10 production was not dependent on BAFF activation (Fig. 6F). 
BAFF-R-deficient EBV-B cells were used as negative controls (Warnatz et al., 2009). 
We conclude that TRAF3 deficiency in P1 affects at least the CD40, LTβR and BAFF-
R pathways, as previously shown in mouse and human cell lines. The lack of a 
corresponding overt clinical phenotype is consistent with an incomplete functional 
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defect. By contrast, complete defects in CD40 (Conley et al., 2009) and, to a lesser 
extent, BAFF-R (Warnatz et al., 2009), have been shown to have clinical consequences. 
We would expect the residual signaling threshold below which predisposition to disease 
occurs to vary between pathways.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 15 
DISCUSSION  
We have identified a patient with a heterozygous de novo R118W germline 
mutation in TRAF3. Previous studies have identified the R118W mutation of TRAF3 as 
a somatic mutation involved in multiple myeloma (Annunziata et al., 2007; Keats et al., 
2007), independently indicating that this allele is deleterious and suggesting that our 
patient might be at risk of this disease. Heterozygosity for the R118W TRAF3 allele 
leads to impairment of the TLR3-dependent induction of type I IFN and IFN-λ, 
resulting in predisposition to HSE. Autosomal dominant TRAF3 deficiency is the third 
genetic etiology of HSE to be identified, after autosomal recessive UNC-93B deficiency 
(Casrouge et al., 2006) and autosomal dominant TLR3 deficiency (Zhang et al., 2007). 
It is a rare genetic etiology of HSE, as no TRAF3 coding mutations have been identified 
in 190 other children with HSE analyzed. TRAF3 deficiency is also the first primary 
immunodeficiency involving a TRAF protein to be identified. The presence of TRAF3 
deficiency in a child with HSE confirms the importance of an intact TLR3-IFN pathway 
for controlling primary HSV-1 infection in the CNS (Zhang et al., 2007). It further 
indicates that TLR3-mediated immunity is not protective with only 10-20% expression 
and function of TRAF3. Mutations in the UNC93B, TLR3, TRIF, and TRAF3 genes each 
affect only a small proportion of children with HSE. These findings suggest that 
predisposition to HSE may result from a collection of diverse, and possibly 
immunologically related single-gene defects (Alcais et al., 2009; Casanova and Abel, 
2007). 
The patient with TRAF3 deficiency and HSE described here is now 18 years old 
and has otherwise remained healthy off any prophylaxis, with normal resistance to other 
infectious diseases, including viral diseases in particular. Residual signaling 
downstream from TLR3 is probably not involved in this resistance, because UNC-93B-
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deficient patients have no detectable residual TLR3 signaling but are nonetheless also 
resistant to common viruses other than HSV-1. Anti-viral IFN responses triggered by 
receptors other than TLR3, whether TRAF3-dependent (somewhat preserved due to the 
incomplete nature of TRAF3 deficiency) or TRAF-3-independent (unaffected by the 
TRAF3 defect), probably account for the normal resistance to viruses observed in this 
TRAF3-deficient patient. With a single 18-year-old patient studied, it is obviously 
impossible to draw firm conclusions regarding the range of infectious phenotypes 
associated with dominant-negative TRAF3 alleles. Other infections may strike this 
patient later in life, and other patients carrying dominant-negative TRAF3 alleles may 
display other infectious phenotypes. Phenotypes other than infectious may also occur. 
The TRAF3 defect also impairs signaling pathways downstream from multiple TNF 
receptors. However, this broad immunological phenotype has had so far no overt 
clinical consequences. This may be transient, as for example the impairment of BAFF 
signaling might perhaps lead to disorders of B cell immunity with increasing age 
(Warnatz et al., 2009). In any case, the weak but detectable residual TRAF3-dependent 
responses in this patient probably account for her survival into adulthood, contrasting 
with the neonatal death of mice with complete TRAF3 deficiency (He et al., 2006; Xu et 
al., 1996). In conclusion, this “experiment of nature” suggests that the first apparent 
clinical consequence of decreases in TRAF3 production and function is predisposition 
to HSE, due to the impairment of TLR3 responses.  
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EXPERIMENTAL PROCEDURES 
Human molecular genetics 
We extracted RNA from Epstein-Barr virus-immortalized lymphoblastoid cell 
lines (EBV-B cells) and immortalized fibroblast cell lines (SV40-fibroblasts), using 
Trizol (Invitrogen, Carlsbad , California, USA), according to the manufacturer’s 
instructions. RNA was reverse transcribed directly, with Oligo-dT (Invitrogen). 
Polymerase chain reaction (PCR) was carried out with Taq polymerase (Invitrogen), 
using the GeneAmp PCR System 9700 (Applied Biosystems, Foster City, California, 
USA). The cDNA exons of TRAF3 were amplified by PCR. The primer sequences used 
for the genomic coding region of TRAF3 are shown below. 
The PCR products were purified by ultracentrifugation through Sephadex G-50 
Superfine resin (Amersham-Pharmacia-Biotech, Buckinghamshire, UK) and sequenced 
with the BigDye Terminator Cycle Sequencing Kit (Applied Biosystems). Sequencing 
products were purified by centrifugation through Sephadex G-50 Superfine resin and 
sequences were analyzed with an ABI Prism 3700 apparatus (Applied Biosystems). 
The mutation was confirmed by the analysis of genomic DNA extracted from 
erythrocytes/granulocytes, EBV-B cells and SV40-fibroblasts. DNA was isolated by 
phenol-chloroform extraction, as previously described (Giraffa et al., 2000). 
TRAF3 sequencing primers: 
Forward primer 
1F: ggaccgcgagatgaggaa 
2F: gctcctggctccctactctt 
3F: taatgctgggacatctgctg 
4F: caactcgctcgaaaagaagg 
5F: agccagcctttctacactgg 
6F: agtagctggggaggtggatt 
 
Reverse primer 
1R: cggtcagtgtgcagctttag 
2R: ctcgcaggtctttcctcaag 
3R: gcttggctgtctatcactcg 
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4R: cgtccccgttcaggtagac 
5R: aaaacgtgtcaggtgtgctc 
6R: actgtatttgaaacaaaattgcac 
 
Multiple amino-acid sequence alignment 
 The Homo sapiens TRAF3 (NP_003291.2) amino-acid sequence was aligned 
with other TRAF3 sequences by BLAST, using the protein database of the National 
Center for Biotechnology Information website (NCBI, 
http://blast.ncbi.nlm.nih.gov/Blast.cgi). Multiple sequence alignment was carried out 
with CLUSTAL W (1.83), based on the TRAF3 amino-acid sequences of Pan 
troglodytes (XP_001164813), Macaca mulatta (XP_001082535.1), Equus caballus 
(XP_001490050.1), Monodelphis domestica (XP_001367040.1), Ornithorhynchus 
anatinus (XP_001507440.1), Mus musculus (NP_035762.2), Sus scrofa 
(XP_001927435.1), Rattus norvegicus (NP_001102194.1), Bos taurus (XP_582595.3), 
Canis familiaris (XP_547989.2), Gallus gallus (XP_421378.1), Oncorhynchus mykiss 
(XP_001507398.1) and Danio rerio (NP_001003513.1). 
 
Cell purification and culture 
Freshly isolated human peripheral blood mononuclear cells (PBMC) were 
isolated by Ficoll-Hypaque density gradient centrifugation (Amersham-Pharmacia-
Biotech) from cytopheresis or whole-blood samples obtained from patients or healthy 
volunteers. PBMCs were stimulated for 40 h, at a density of 2 x 106 cells/ml, in RPMI 
1640 (Invitrogen) supplemented with 10% fetal calf serum (FCS) (Invitrogen).  
Primary human fibroblasts were obtained from biopsies of patients or healthy 
controls, and were cultured in DMEM (Invitrogen) supplemented with 10% FCS. They 
were then transformed with an SV40 vector, as previously described (Chapgier et al., 
2006), to create immortalized fibroblast cell lines: SV40-fibroblasts. The SV40-
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fibroblast cell lines were activated in 24-well plates, at a density of 105 cells/well, for 24 
h (or 2, 10 and 24 h in the poly(I:C) kinetic studies).  
EBV-B cell lines were obtained from patients and normal donors as previously 
described (Pellat-Deceunynck et al., 1999). BAFFR-/- EBV-B cells were kindly 
provided by Klaus Warnatz, PhD. EBV-B cells were cultured in RPMI medium 
supplemented with 10% FCS and were activated in 6-well plates, at a density of 5 x106 
cells/well, for 24 h.   
For the differentiation and culture of monocyte-derived dendritic cells 
(MDDCs), PBMCs freshly isolated by Ficoll-Hypaque density gradient centrifugation 
from healthy controls and patients, were incubated in RPMI 1640 supplemented with 
10% FCS, in cell culture flasks, for 1 hour, at 37°C, under an atmosphere containing 5% 
CO2. The adherent cells (monocytes) were cultured for 8 days in RPMI 1640 
supplemented with 10% FCS, in the presence of GM-CSF (R&D Systems, Minneapolis, 
MN, USA, 50 ng/ml) and IL-4 (R&D Systems, 10 ng/ml). The differentiation and purity 
of these cells were confirmed by staining with antibodies directed against CD1a (PE, 
BD Pharmingen, San Diego, CA, USA) and CD14 (FITC, Becton Dickinson) or a 
conjugated mouse IgG1 isotype control (PE or FITC, Becton Dickinson). Stained cells 
were analyzed by flow cytometry (FACSCanto flow cytometer, Becton Dickinson). For 
stimulation, the cells were plated at a density of 0.25 x 105 cells/well in 48-well tissue 
culture plates and cultured in the presence of GM-CSF and IL-4; MDDCs were 
stimulated for 24 h.  
For the differentiation and culture of monocyte-derived macrophages (MDM), 
PBMCs freshly isolated by Ficoll-Hypaque density gradient centrifugation from healthy 
controls and patients were incubated in RPMI 1640 supplemented with 10% FCS, in 
cell culture flasks, for 1 hour, at 37°C, under an atmosphere containing 5% CO2. The 
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adherent cells (monocytes) were cultured for 10 days in RPMI 1640 supplemented with 
10% FCS, in the presence of Rh-M-CSF (R&D Systems, 10 µg/ml). For stimulation, the 
cells were plated at a density of 0.25 x 105 cells/well in 96-well tissue culture plates and 
stimulated for 24 h. 
All cells were grown at 37°C, under an atmosphere containing 5% CO2. 
 
Determination of mRNA levels by Q-PCR 
Total RNA was extracted from EBV-B cells, SV40-fibroblasts RAW, and 
RAWTRAF3-/- cells, untransfected or transfected. In some cases, the cells were 
stimulated with 25 µg/ml poly(I:C) (InvivoGen, San Diego, CA, USA) for 4 hours. 
RNA was reverse transcribed directly, using Oligo-dT, to determine TRAF3, IFN-β and 
IFN-λ mRNA levels. The β-glucuronidase (GUS) or 18S rRNA gene was used for 
normalization. Quantitative real-time PCR (Q-PCR) was performed with Applied 
Biosystems Assays-on-Demand™ probe/primer combinations and 2 x universal reaction 
mixture, in an ABI PRISM® 7700 Sequence Detection System. Results are expressed 
using the ∆∆Ct method, as described by the manufacturer. 
 
Immunoblots 
Total cell extracts were prepared from SV40-fibroblasts, EBV-B cells and RAW 
and RAW-TRAF3-/- cells, either not transfected or stably transfected with pWPI, pWPI-
TRAF3, pBABE or pBABE-TRAF3-R118W. In some cases, SV40-fibroblasts were 
activated by incubation with 25 µg/ml poly(I:C) for 24 h. Equal amounts of protein 
from each sample were separated by SDS-PAGE and blotted onto iBlot TM Gel Transfer 
Stacks (Invitrogen). These nitrocellulose membranes were then probed with anti-
TRAF3 polyclonal antibody (Abcam, Cambridge, MA, USA) or anti-NF-kB2 p100/p52 
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(18D10) rabbit mAb (human specific) (Cell Signaling Beverly, MA, USA) followed by 
a secondary horseradish-conjugated donkey anti-rabbit IgG (GE Healthcare, 
Buckinghamshire, UK). Membranes were stripped and reprobed with an antibody 
against GADPH (Santa Cruz Biotechnology Inc., Santa Cruz, CA), to control for 
protein loading. Antibody binding was detected by enhanced chemiluminescence (ECL; 
Amersham-Pharmacia-Biotech). Antibody-2 is an anti-TRAF3 polyclonal antibody 
(Cell Signaling Technology).  
 
Stimulations 
We used the following Toll-like receptor (TLR) agonists: a synthetic analog of 
dsRNA, polyinosinepolycytidylic acid (poly(I:C), a TLR-3 agonist, at a concentration of 
25 µg/ml);  lipopolysaccharide (LPS Re 595 from Salmonella minnesota, a TLR-4 
agonist, at 10 µg/ml; Sigma, St Louis, MO, USA); resiquimod hydrochloride (R-848, a 
TLR-7 and -8 agonist, at 3 µg/ml; GLSynthesis Inc., Worcester, MA, USA); IL-1β (at 
20 ng/ml; R&D Systems Inc.); TNF-α (at 20 ng/ml; R&D Systems Inc.). All agonists 
and reagents were endotoxin-free. For all stimulations of PBMCs with TLR agonists 
other than LPS, cells were incubated with polymyxin B (10 µg/ml) (Sigma) at 37°C, for 
30 minutes before activation.  
For RIG-I/MDA5 stimulation, we used 0.25 µg of poly(I:C) or 0.1 µg of non 
coding RNA (7sk-as), kindly provided by Caetano Reis e Sousa (Pichlmair et al., 2006), 
and carried out transfection with LipofectamineTM Reagent (Invitrogen), according to 
the kit manufacturer’s instructions. 
 LTα1β2 (R&D Systems, 65 ng/ml) was used to activate lymphotoxin-β receptor 
(LTβR), with or without IFN-γ (Imukin; Boehringer Ingelheim, Ingelheim, Germany), 
at a concentration of 80 IU/ml. B cell-activating factor receptor (BAFF-R) was activated 
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with human BAFF (Miltenyi Biotec, Bergisch Gladbach, Germany) at a concentration 
of 100 ng/ml.  
For viral stimulation, we used: 1) dsDNA viruses: herpes simplex virus-1 (HSV-
1, strain KOS-1, multiplicity of infection (MOI) = 1); HSV-1 inactivated by ultraviolet 
(UV) radiation (HSV-1i); BK virus (BKV, an isolate from a patient, provided by Pierre 
Lebon, Paris, France, MOI= 0.02). 2) ss(-)RNA viruses: vesicular stomatitis virus 
(VSV, strain Indiana, MOI= 1), Newcastle disease virus (NDV, strain BR24 444, MOI 
= 0.5), measles virus (measles V, strain Edmonston, MOI = 0.004), Sendai virus (Sendai 
V, strain E92, MOI= 12.5), parainfluenza virus III (para-III, strain EA102, MOI= 0.04), 
mumps virus (mumps V, vaccine strain Urabe, MOI = 0.04). 3) ss(+)RNA viruses: 
sindbis virus (sindbis V, strain VR1248 ATCC, MOI= 0.2), encephalomyocarditis virus 
(EMCV, MOI = 0.1). 
In some experiments, cells were treated with IFN-α (intron A, Schering-Plough, 
Kenilworth, NJ, USA) at a concentration of 105 IU/ml before stimulation. CD40 was 
activated in MDDC, as previously described (Filipe-Santos et al., 2006). In EBV-B 
cells, CD40 was activated with soluble human MegaCD40LTM(ENZO Life Science Inc., 
Farmingdale, NY, USA) at a concentration of 2 µg/ml. 
Cell supernatants were recovered and their cytokine concentrations determined 
by ELISA. 
 
Cytokine determinations 
The production of IFN-α, -β, -λ, IL-6, IL-8, IL-10, IL-12p40 and TNF-α was 
assessed by ELISA. An ELISA was carried out for each of IFN-α (AbCys SA, Paris, 
France), IFN-β (TFB, Fujirebio, Inc., Tokyo, Japan), IL-6, IL-8, IL-10, TNF-α 
(Sanquin, Amsterdam, Holland), IL-12p40 and mouse IFN-β (R&D Systems), 
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according to the kit manufacturer’s instructions. The ELISA for IFN-λ was carried out 
as previously described (Zhang et al., 2007). 
 
Signal transduction studies in SV40-fibroblasts 
Cell nuclear extracts were prepared from SV40-fibroblasts, following incubation 
with or without Poly(I:C), TNF-α and IL-lβ. NFkB ELISA (Active Motif, Calrsbad, 
CA, USA) was carried out according to the kit manufacturer’s instructions.  
For the detection of IRF-3 dimerization, whole-cell extracts were prepared from 
SV40-fibroblasts with or without Poly(I:C) (25 µg/ml) treatment for 1 or 2 h. The IRF-3 
monomers and dimers were separated by native PAGE in the presence of 1% sodium 
deoxycholate (DOC) (Sigma). Total cell extracts (50 µg of protein) were diluted 1:5 in 
non denaturing sample buffer (312.5 mM Tris–HCl, pH 6.8, 50% glycerol, 0.05% 
bromophenol blue and 5% DOC) and separated by electrophoresis in a 7.5% 
polyacrylamide gel, in 25 mM Tris and 192 mM glycine, pH 8.4, with 1% DOC present 
in the cathode chamber only. The gel was blotted onto a membrane, which was then 
probed with the anti-IRF-3 antibody (FL-425, Santa Cruz Biotechnology) followed by a 
secondary horseradish-conjugated anti-rabbit IgG. 
 
Cell viability assay 
The viability of SV40-fibroblasts was assessed by resazurin oxidoreduction 
(TOX-8) (Sigma). Cells were plated, in triplicate, in 96-well flat-bottomed plates (2 x 
104 cells/well), in DMEM supplemented with 2% FCS; 24 hours later, cells were 
infected by incubation for 24 hours with VSV at the indicated multiplicity of infection 
(MOI). Resazurin dye solution was then added (5 µl per well) to the culture medium, 
and the samples were incubated for an additional two hours at 37°C. Fluorescence was 
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then measured at a wavelength of 590 nm, using an excitation wavelength of 531 nm. 
Background fluorescence, calculated for dye and complete medium alone (in the 
absence of cells) was then subtracted from the values for all the other samples; 100% 
viability corresponds to the fluorescence of uninfected cells. For assays of cell 
protection upon viral stimulation, cells were treated with IFN-α (105 IU/ml) for 24 
hours before infection, and during infection. 
 
Viral infection  
For viral infection, 105 SV40-fibroblasts were plated in individual wells of 24-
well plates and infected, at a MOI of 10, in DMEM supplemented with 2% FCS. The 
Stat-1-deficient patient studied has been described elsewhere (2). After 30 minutes, cells 
were washed and incubated in 500 µl of medium. The supernatants were frozen at the 
time points indicated in the figures. Viral titers were determined by calculating the 50% 
tissue culture infectious dose (TCID50), as described by Reed and Muench, after the 
inoculation of Vero cell cultures in 96-well plates. For assays of cell protection upon 
viral stimulation, cells were treated with IFN-α (105 IU/ml) for 18 hours before 
infection, as appropriate. 
 
Determination of cell death via the LTβR pathway 
We assessed levels of SV40-fibroblast cell death via the LTβR pathway by 
TOX-8 assays. Cells were plated, in triplicate, in 96-well flat-bottomed plates (2 x 104 
cells/well), in DMEM supplemented with 2% FCS; 24 hours later, cells were treated 
with LTα1β2 (65 or 100 ng/ml), with or without IFN-γ at a concentration of 80 IU/ml 
and incubated for 72 h. Resazurin dye solution was then added (5 µl per well) to the 
culture medium, and the samples were incubated for an additional two hours at 37°C. 
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Fluorescence was then measured at a wavelength of 590 nm, using an excitation 
wavelength of 531 nm. Background fluorescence, calculated for dye and complete 
medium alone (in the absence of cells) was then subtracted from the values for all the 
other samples; 100% viability corresponds to the fluorescence of non stimulated cells.  
 
Site-directed mutagenesis and cloning 
Site-directed mutagenesis was performed with QuikChange®II XL (Stratagene, 
La Jolla, CA, USA), using the pCR4.0-TRAF3 plasmid (kindly provided by Jonathan 
Keats, PhD). The TRAF3-R118W gene generated by mutagenesis was inserted into the 
pBABE-puro expression vector (Addgene, Cambridge, MA, USA) (pBABE-TRAF3-
R118W).  
Two TRAF3 C-terminal deletions without amino acids 289-568 were created in 
the pBABE-puro expression vector: 
- pBABE-TRAF3-∆(289-568) 
- pBABE-TRAF3-R118W-∆(289-568) 
 
Stable transfections 
Cells (SV40-fibroblasts, RAW and RAW-TRAF3-/- cells (kindly provided by 
Michael Karin, PhD)) were transfected by electroporation at 250 V and 960 mF, in 
phosphate-buffered saline (107 cells/ 0.5 ml). We used 5 µg of pWPI-TRAF3 (kindly 
provided by Jonathan Keats, PhD) or pBABE-TRAF3-R118W, linearized with FspI 
(New England Biolabs, Beverly, MA, USA), for transfection. Transfectants were 
selected by sorting cells expressing green fluorescent protein (GFP) for pWPI-TRAF3, 
or in 0.5 mg/ml puromycin 24 h after electroporation for pBABE-TRAF3-R118W. The 
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presence of TRAF3 was checked by Q-PCR and western blotting. The same conditions 
were used for the transfection of cells with mock vectors. 
 
Transient transfections 
RAW and RAW-TRAF3-/- cells were transfected with 2 µg of plasmid (all derived from 
the pBABE-puro expression vector) at various ratios, in the presence of the FuGENE 
®HD Transfection Reagent (Roche Applied Science, Indianapolis, IN, USA), according 
to the kit manufacturer’s instructions. 
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FIGURE LEGENDS 
Fig. 1. Heterozygous TRAF3 mutation in a child with HSE (P1)  
(A) Family pedigree, with allele segregation. The patient with HSE, in black, is 
heterozygous for the mutation. (B) Heterozygous c.352C>T mutation in patient 1 (P1). 
The sequence of the polymerase chain reaction products of genomic DNA from 
leukocytes of a control (C) and P1 is shown. (C) Schematic representation of TRAF3 
protein structure. Human TRAF3 has eleven exons, encoding a protein composed of a 
ring finger and five zinc-finger domains in the N-terminal region, followed by an 
isoleucine zipper and a TRAF domain in the C-terminal region. P1 carries the c.352C>T 
mutation, which results in an arginine (R) to tryptophan (W) substitution at amino-acid 
position 118 (R118W) in the first zinc-finger domain.  
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Fig. 2. TRAF3 expression levels and TLR3 response of a child with HSE (P1) 
(A) (Top) TRAF3 mRNA expression in SV40-fibroblasts from a control (C) and P1. β-
glucuronidase (GUS) was used for normalization. (Bottom) Representative immunoblot 
analysis of TRAF3 in SV40-fibroblasts from a control (C) and P1. TRAF3 (%) indicates 
densitometry results, normalized with respect to GADPH and expressed as a percentage 
of control TRAF3. The control is a representative example of the five controls analyzed. 
(B) (Top) TRAF3 mRNA levels normalized with respect to 18S rRNA and (Bottom) 
immunoblot analysis of TRAF3 in RAW cells and RAW Traf3-/- cells not transfected 
and stably transfected with human wild-type (WT) (pWPI-TRAF3) or R118W mutant 
TRAF3 (pBABE-TRAF3-R118W) constructs. As a negative control, we transfected 
cells with a mock WT vector (Mock-1, pWPI) or with a mock R118W mutant vector 
(Mock-2, pBABE). TRAF3 (%) indicates densitometry results normalized with respect 
to GADPH amounts and expressed as a percentage of TRAF3 amounts in RAW cells. 
(C) Production of IFN-β (measured in structural units, IU/ml), IFN-λ and IL-6 by 
SV40-fibroblasts after poly(I:C) stimulation (25 µg/ml), at various time points (left 
panels) and for various doses of poly(I:C), for 24 hours (right panels), as assessed by 
ELISA. C is the positive control and P1 is patient 1; UNC93B-/- is the UNC-93B-
deficient patient. (D) NF-κB ELISA of nuclear extracts from SV40-fibroblasts from a 
control (C), P1 and a NEMO-deficient patient (negative control), after stimulation with 
TNF-α and IL-1β for 30 minutes, or stimulation with poly(I:C) for 120 minutes. (E) 
IRF-3 monomers and dimers in total cell extracts of SV40-fibroblasts from a control (C) 
and P1, after stimulation with poly(I:C) for 1 and 2 hours, as assessed by immunoblot. 
TLR3- and UNC-93B-deficient patients were used as negative controls.  
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Fig. 3. Complementation of the patient’s cells and dominant negative effect 
(A) Immunoblot analysis of TRAF3 amounts in SV40-fibroblasts from a control (C) 
and P1, not transfected (P1) and stably transfected with human WT TRAF3 (P1 WT) or 
mock vector (P1-mock), with and without stimulation with poly(I:C) for 24 h. TRAF3 
(%) indicates densitometry results normalized with respect to GADPH amounts and 
expressed as a percentage of control TRAF3 amounts. (B) Production of IFN-β and IL-
6, as assessed by ELISA, in SV40-fibroblasts from a control (C), P1, an UNC-93B-
deficient patient (UNC93B-/-), P1 cells transfected with human WT TRAF3 (P1-WT) or 
mock vector (P1-mock). (C) Immunoblot analysis of TRAF3 amounts in RAW cells, 
non transfected RAW Traf3-/- cells, and RAW cells stably transfected with R118W 
mutant TRAF3 (R118W), WT TRAF3 (WT) or mock vector (Mock). (D) IFN-β 
production, as assessed by ELISA, in RAW cells, not transfected or transfected with 
R118W mutant TRAF3 or mock vector. All transfections generated stable cell lines. 
Glyceraldehyde phosphate dehydrogenase (GADPH) was used as an internal expression 
control for WB. The panels illustrate results from a single experiment, representative of 
three. Mean values + SD were calculated from three independent experiments. 
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Fig. 4. SV40-fibroblast studies: production of type I IFN and cytokines  
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(A) Production of IFN-β, IFN-λ and IL-6 after stimulation with VSV, as assessed by 
ELISA, in SV40-fibroblasts from a control (C), P1 and an UNC-93B-deficient patient 
(UNC93B-/-). (B) Viable cell percentages, estimated by resazurin oxidation/reduction, 
for SV40-fibroblasts from a healthy control (C), P1, TLR3+/-, UNC93B-/- and STAT1-/-
patients, 24 h after infection with VSV, at various multiplicities of infection. The cells 
were either not treated (left panel), or were subjected to prior treatment (right panel) 
with recombinant IFN-α for 18 hours. (C) VSV titers, estimated on Vero cells, in SV40-
fibroblasts from a healthy control (C), P1, STAT1 -/-, UNC93B -/- and TLR3 +/- patients, 
at various times after VSV infection without (left panel) or with (right panel) 18 hours 
of pretreatment with IFN-α. (D) The production of IFN-β and IL-6, assessed by ELISA, 
in SV40-fibroblasts from a control (C), P1 (UNC93B -/-), P1 SV40-fibroblasts 
transfected with human WT TRAF3 (P1-WT) or mock vector (P1-mock). (E) Viable 
cell percentages, estimated by resazurin oxidation and reduction, for SV40-fibroblasts 
from a healthy control (C), P1, P1 cells transfected with WT TRAF3 (P1-WT) and P1 
cells transfected with mock vector (P1-mock), 24 hours after infection with VSV, at 
various multiplicities of infection. The cells were either not treated (left panel), or 
subjected to prior treatment (right panel) with recombinant IFN-α for 18 hours. (F) 
VSV titers, estimated on Vero cells, in SV40-fibroblasts from a healthy control (C), P1, 
P1 cells transfected with WT TRAF3 (P1-WT) or mock vector (P1-mock), at various 
times after VSV infection, without (left panel) or with (right panel) 18 hours of 
pretreatment with IFN-α. Mean values + SD were calculated from three independent 
experiments. 
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Fig. 5. Production of type I IFN and cytokines in immune system cells 
(A) Production of IFN-α and IL-12p40 after stimulation with LPS and R-848, as 
assessed by ELISA, in MDDCs. C is the positive control (one of the eight controls 
tested) and P1 is patient 1. (B) Production of IFN-λ and IL-12p40 after stimulation with 
LPS and R-848, as assessed by ELISA, in MDMs. C is the positive control (one of the 
eight controls tested) and P1 is patient 1. (C) Production of IFN-β, IFN-λ and IL-6, as 
assessed by ELISA, in SV40-fibroblasts after stimulation with poly(I:C)+Lipofectamine 
or 7sk-as. C is the positive control and P1 is patient 1; UNC93B -/- is an UNC-93B-
deficient patient. (D) IFN-α production after stimulation with poly(I:C) and various 
viruses, as assessed by ELISA, in PBMCs. C is the positive control and P1 is patient 1. 
The panel illustrates results from a single experiment, representative of two. (E) 
Production of IFN-β and IFN-λ, as assessed by ELISA, in SV40-fibroblasts after 
stimulation with HSV-1. C is the positive control and P1 is patient 1; UNC93B -/- is an 
UNC-93B-deficient patient. Mean values + SD were calculated from three independent 
experiments. (F) Production of IFN-β and IFN-λ, as assessed by ELISA, in SV40-
fibroblasts, after stimulation with various viruses. C is the positive control and P1 is 
patient 1; UNC93B -/-, TLR3 +/- and MyD88 -/- are patients with the corresponding 
genotypes.  
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Fig. 6. TRAF3 in TNFR pathways  
The production of IL-6 (A) and IL-12p40 (B) was assessed by ELISA in MDDC, after 
24 h of incubation with L-cells transfected with human CD40L (CD40L) and non 
transfected L-cells (Neg control), for a healthy control (C) and P1. (C) Cell death assay, 
based on resazurin oxidation/reduction, for SV40-fibroblasts from a healthy control (C) 
and P1 treated with various doses of LTα1β2, with or without IFN-γ (80 IU/ml) for 72 
h. (D) IL-8 production, assessed by ELISA, in SV40-fibroblasts from control (C), P1, 
P1 cells transfected with human WT TRAF3 (P1-WT) or mock vector (P1-mock), after 
activation with LTα1β2 at the concentration indicated. (E) WB analysis of the p52 
subunit in EBV-B cells not stimulated (NS) or stimulated with BAFF at a concentration 
of 100 ng/ml (BAFF). C is the positive control, P1 is patient 1 and BAFFR -/- is EBV-B 
cells from a BAFFR-deficient patient. “Fold induction” indicates densitometry results 
normalized with respect to GADPH levels, expressed as a fold induction over non 
stimulated control cells. GADPH was used as an internal control for WB. The panel 
illustrates results from a single experiment, representative of three. (F) IL-10 
production, assessed by ELISA, in EBV-B cells, after BAFF activation (100 ng/ml). C 
is the positive control; P1 is patient 1 and BAFFR -/- is a BAFFR-deficient patient. Mean 
values + SD were calculated from three independent experiments. 
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